UNITY presents 12-week data from phase II study of UBX-0101 in painful osteoarthritis of the knee Aug. 18, 2020
Fulcrum looks for balance in its phase II FSHD study Aug. 11, 2020 By Lee Landenberger An interim analysis from Fulcrum Therapeutics Inc.’s phase II study of losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD) produced data that pleased the CEO and displeased investors.Read More
RSS
